Minor Use Minor Species Development of Drugs (R01)
Food and Drug Administration · Opportunity PAR-24-216
Application Due Dates are as follows: July 29, 2024; January 31, 2025; July 25, 2025; January 30, 2026; July 24, 2026; January 29, 2027
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities
- Native American tribal organizations (other)
- Nonprofits with 501(c)(3), other than higher education
- Nonprofits without 501(c)(3)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
• Faith-based or Community-based Organizations• Regional Organizations• Non-domestic (non-U.S.) Entities (Foreign Organizations)
About this opportunity
This Notice of Funding Opportunity (NOFO) is issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), and solicits Research Project (R01) grant applications from institutions or organizations that propose to develop or support the development of designated new animal drugs intended for minor uses in major species or for use in minor species (MUMS). The FDA is authorized to provide grants to assist in defraying the costs of qualified safety and effectiveness testing that could be used to satisfy the requirements for FDA approval of MUMS-designated drugs. Only entities developing drugs for veterinary use or parties working as research partners with such entities are eligible for grants. The organization (or applicant) seeking approval of the new animal drug under investigation must have opened an Investigational New Animal Drug (INAD) file with FDA/CVM and must hold a minor use or minor species "designation" granted by FDA/CVM's Office of Minor Use and Minor Species Animal Drug Development (OMUMS) for that drug for a specified intended use, in accordance with the provisions of section 573 of the Food, Drug and Cosmetic Act (21 U.S.C. 360ccc-2) and 21 CFR part 516. FDA/CVM's Office of New Animal Drug Evaluation (ONADE) must have reviewed and concurred with the proposed study protocol before an applicant can submit a grant application.
Portfolio context — this listing covers more than this opportunity
This opportunity is funded under Assistance Listing 93.103 (“Food and Drug Administration Research”), a broad federal program that made about 133 new awards per year over the last five fiscal years (median award $500k). Those figures describe that whole portfolio — not this specific solicitation, so we don't show them as if they were this opportunity's track record.
Applicant counts per solicitation are not published by any federal agency — no one can honestly sell you that number.
Don't want to hunt for grants like this one? Get free deadline alerts for your state and focus areas.
Consultant or grant writer? See the client-ready Opportunity Brief for this grant — actual award sizes vs. the advertised ceiling, who wins, printable "prepared for your client" version.
Similar grants still open
| Opportunity | Agency | Deadline | Award ceiling | Eligible |
|---|---|---|---|---|
| Animal Food Regulatory Program Standards Implementation Development and Maintenance, with Mutual Reliance Initiatives Clinical Trials Not Allowed | Food and Drug Administration | April 1, 2027 | $300k | |
| NARMS Cooperative Agreement Program to Strengthen Antibiotic Resistance Surveillance in Retail Food Specimens | Food and Drug Administration | April 1, 2027 | $200k | |
| Laboratory Flexible Funding Model (LFFM) | Food and Drug Administration | January 11, 2028 | $1.5M | |
| Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional) | Food and Drug Administration | February 8, 2028 | $600k |